SB 247853 | 200711-10-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: SB 247853
• 英文别名: 5-Methyl-1-[2-(pyridin-2-ylmethyloxy)pyridin-5-ylcarbamoyl]-6-trifluoromethylindoline；Unii-jbj4vct98Y；5-methyl-N-[6-(pyridin-2-ylmethoxy)pyridin-3-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide
• CAS: 200711-10-0
• 化学式: C₂₂H₁₉F₃N₄O₂
• 分子量: 428.414
• InChiKey: KLAHZRONIHBPPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  SB 247853 在 (η-1,5-cyclooctadiene)(pyridine)(tricyclohexylphosphine)iridium(I) tetrafluoroborate 超重氢 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Direct tritium labeling of multifunctional compounds using organoiridium catalysis. 2.

  摘要：

  A variety of complex compounds have been labeled with tritium gas by catalytic exchange in the presence of catalyst precursors [(cod)Ir(dppe)]BF4 or [(cod)Ir(py)(PCy3)]BF4. In most cases, predictable regioselectivity and high specific activities are achieved. These results are compared in some cases to the results of labeling related compounds with [(cod)Ir(PPh3)(2)]BF4. Prereduction of the catalyst precursors in situ with hydrogen allows the use of smaller quantities of tritium gas and reduces the amount of radioactive waste. Two or more compounds can be labeled simultaneously as mixtures then separated in the HPLC purification step to increase compound throughput.

  DOI：

  10.1002/(sici)1099-1344(199908)42:8<797::aid-jlcr240>3.0.co;2-o
• 作为产物：
  描述：

  5-甲基-6-三氟甲基吲哚啉 、 Phenyl N-[2-(pyridin-2-ylmethyloxy)pyridin-5-yl]carbamate 、 三乙胺 、 水 在 水 、 crude product 、 silica gel 、 methanol-dichloromethane 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以to give the title compound (0.35 g, 55%), m.p. 219-20° C.的产率得到SB 247853
  参考文献：
  名称：

  Indoline derivatives useful as 5-HT-2C receptor antagonists

  摘要：

  本发明提供了作为5HT2C受体拮抗剂有用的吲哚啉衍生物，并提供了使用它们治疗各种中枢神经系统疾病的方法。

  公开号：

  US06313145B1

文献信息

• NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT
  申请人：SEONG Churlmin

  公开号：US20090258876A1

  公开（公告）日：2009-10-15

  Disclosed herein are a new indole carboxylic acid bispyridyl carboxamide derivative, a preparation method thereof, and a composition for prevention or treatment of obesity, urinary disorders, and CNS disorders, containing the same as an active ingredient. Because the indole carboxylic acid bispyridyl carboxamide derivatives according to the present invention have high affinity for 5-HT 2c receptors, act selectively on the 5-HT 2c receptors, the derivatives rarely have adverse effects caused by other receptors. Because the derivatives effectively inhibit serotonin activity, they may be useful for treatment or prevention of obesity; urinary disorders such as urinary incontinence, premature ejaculation, erectile dysfunction, and prostatic hyperplasia; CNS disorders such as depression, anxiety, concern, panic disorder, epilepsy, obsessive-compulsive disorder, migraine, sleep disorder, withdrawal from drug abuse, Alzheimer's disease, and schizophrenia, associated with 5-HT 2c receptors.

  本公开涉及一种新的吲哚羧酸双吡啶羧酰胺衍生物，其制备方法，以及包含该衍生物作为活性成分的用于预防或治疗肥胖、泌尿系统疾病和中枢神经系统疾病的组合物。根据本发明的吲哚羧酸双吡啶羧酰胺衍生物具有高亲和力5-HT2c受体，对5-HT2c受体选择性作用，这些衍生物很少出现由其他受体引起的不良反应。由于这些衍生物有效抑制5-羟色胺活性，它们可能对治疗或预防肥胖；泌尿系统疾病，如尿失禁、早泄、勃起功能障碍和前列腺增生；以及与5-HT2c受体相关的中枢神经系统疾病，如抑郁症、焦虑症、关注症、恐慌症、癫痫、强迫症、偏头痛、睡眠障碍、戒毒、阿尔茨海默病和精神分裂症可能有用。
• Electrospun pharmaceutical compositions
  申请人：——

  公开号：US20030017208A1

  公开（公告）日：2003-01-23

  The present invention is directed to an electrospun pharmaceutical composition comprising a pharmaceutically acceptable actibe agent, and a pharmaceutically acceptable polymeric carrier for use in therapy.

  本发明涉及一种电纺制备的药物组合物，包括一种药学上可接受的活性药物和一种药学上可接受的聚合物载体，用于治疗。
• [EN] INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE L'INDOLINE UTILES COMME ANTAGONISTES DES RECEPTEURS 5HT-2C
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1997048700A1

  公开（公告）日：1997-12-24

  (EN) The invention relates to heterocyclic compounds of formula (I) or a salt thereof wherein R1 is hydrogen or C1-6 alkyl; R2, R3 and R4 groups are independently hydrogen, halogen or C1-6 alkyl optionally substituted by one or more fluorine atoms, having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.(FR) L'invention concerne des composés hétérocycliques de formule (I), dans laquelle R1 est hydrogène ou alkyle C1-C6, et les groupes R2, R3 et R4 sont indépendamment hydrogène, halogène ou alkyle C1-C6 éventuellement substitués par un ou plusieurs atomes de fluor, et leurs sels, ces composés ayant une activité pharmacologique. L'invention concerne également des procédés permettant de les préparer et des compositions les contenant, ainsi que leur utilisation dans le traitement des troubles du système nerveux central tels que l'angoisse.

  本发明涉及式（I）的杂环化合物或其盐，其中R1是氢或C1-6烷基；R2、R3和R4基团独立地是氢、卤素或C1-6烷基，可选地被一个或多个氟原子取代，具有药理活性，还涉及其制备方法、含有它们的组合物以及它们在治疗中枢神经系统疾病如焦虑症中的使用。
• Novel indol carboxylic acid bispyridyl carboxamide derivatives as 5-HT2c receptor antagonists
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：EP2108649A1

  公开（公告）日：2009-10-14

  Disclosed herein are a new indole carboxylic acid bispyridyl carboxamide derivative, a preparation method thereof, and a composition for prevention or treatment of obesity, urinary disorders, and CNS disorders, containing the same as an active ingredient. Because the indole carboxylic acid bispyridyl carboxamide derivatives according to the present invention have high affinity for 5-HT2c receptors, act selectively on the 5-HT2c receptors, the derivatives rarely have adverse effects caused by other receptors. Because the derivatives effectively inhibit serotonin activity, they may be useful for treatment or prevention of obesity; urinary disorders such as urinary incontinence, premature ejaculation, erectile dysfunction, and prostatic hyperplasia; CNS disorders such as depression, anxiety, concern, panic disorder, epilepsy, obsessive-compulsive disorder, migraine, sleep disorder, withdrawal from drug abuse, Alzheimer's disease, and schizophrenia, associated with 5-HT2c receptors.

  本发明公开了一种新的吲哚羧酸双吡啶基羧酰胺衍生物、其制备方法以及一种用于预防或治疗肥胖症、泌尿系统疾病和中枢神经系统疾病的组合物，其中含有该衍生物作为活性成分。由于根据本发明的吲哚羧酸双吡啶羧酰胺衍生物对 5-HT2c 受体具有高亲和力，选择性地作用于 5-HT2c 受体，因此该衍生物很少有其他受体引起的不良反应。由于本发明的衍生物能有效抑制血清素活性，因此可用于治疗或预防肥胖症；泌尿系统疾病，如尿失禁、早泄、勃起功能障碍和前列腺增生；中枢神经系统疾病，如抑郁症、焦虑症、忧虑症、恐慌症、癫痫、强迫症、偏头痛、睡眠障碍、药物滥用戒断、阿尔茨海默病和精神分裂症等与5-HT2c受体有关的疾病。
• INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0912556A1

  公开（公告）日：1999-05-06